Compare CVCO & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVCO | TVTX |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.7B |
| IPO Year | 1994 | 2013 |
| Metric | CVCO | TVTX |
|---|---|---|
| Price | $605.82 | $50.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $662.00 | $75.21 |
| AVG Volume (30 Days) | 75.6K | ★ 1.8M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.79 | ★ 92.89 |
| EPS | ★ 5.43 | N/A |
| Revenue | ★ $2,142,713,000.00 | N/A |
| Revenue This Year | $9.17 | $47.49 |
| Revenue Next Year | $7.74 | $48.73 |
| P/E Ratio | $100.27 | ★ N/A |
| Revenue Growth | ★ 31.68 | N/A |
| 52 Week Low | $443.34 | $22.59 |
| 52 Week High | $713.01 | $68.73 |
| Indicator | CVCO | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.18 | 35.14 |
| Support Level | $558.79 | $49.46 |
| Resistance Level | $630.48 | $59.93 |
| Average True Range (ATR) | 21.27 | 2.20 |
| MACD | 6.65 | 0.21 |
| Stochastic Oscillator | 78.83 | 16.43 |
Cavco Industries Inc designs and produces factory-built homes distributed through a network of independent and company-owned retailers, planned community operators and residential developers. It is also a producer of park model RVs, vacation cabins and Factory-built commercial structures. It operates principally in two segments: factory-built housing, which includes wholesale and retail factory-built housing operations and Financial services, which include manufactured housing consumer finance and insurance. The factory-built housing segment generates the majority of revenue from building and selling manufactured and modular homes to both wholesale customers and end consumers through company owned retail stores.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.